In a deal potentially worth up to $800 million, Tarsus Pharmaceuticals Inc. plans to acquire Alkeus Pharmaceuticals Inc., gaining ownership of the once-daily oral therapy ALK-001 (gildeuretinol) for Stargardt disease. “We are investing in assets with novel disease-modifying approaches, compelling clinical evidence and a clear strategic fit to build a leading eye care company,” Bobby Azamian, CEO and chairman of Irvine, Calif.-based Tarsus, said in an investor call. “ALK-001 is exactly that – as